CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to identify new drug targets by investigating the molecular networks that influence receptor tyrosine kinase signaling during cancer progression. It focuses on understanding how these networks can be manipulated to develop second-line therapies for cancer treatment.
Cancer is a major socio-economic problem in EU, with approximately 2.5 million cases diagnosed and 1.2 million deaths every year, and an annual estimated cost of 15 billion € for cancer therapy.
Understanding the molecular mechanisms underlying cancer progression have revolutionized the field of targeted therapies, generating a growing number of inhibitors approved for use in the clinic.
In particular, drugs targeting receptor tyrosine kinases (RTKs) have been successful.
Although several of the…
THE UNIVERSITY OF BIRMINGHAM
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
